Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Fig. 3

Forest plot of unstratified HRs for investigator-assessed PFS by treatment group and patient subgroup. CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; G-CHOP, obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; HR, hazard ratio; IPI, International Prognostic Index; KM, Kaplan–Meier; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us